Anupam Rasayan India Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹636Cr
- +27.2% YoY
- +24.2% QoQ
- Net profit
- ₹56Cr
- −11.1% YoY
- −8.2% QoQ
- Margin
- 22%
- −7 pp YoY
- −3 pp QoQ
Guidance rank: #22 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals. Anupam Rasayan expects a 20-30% CAGR growth over the next 3-5 years in standalone business revenues, driven primarily by Pharma and Polymer segments.
From Anupam Rasayan India Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals.
- Order book at INR14,000 crores indicates potential INR1,700-1,800 crores additional incremental annual revenue mainly from agro and polymer segments.
- Pharma segment contribution has grown from near 0% to 20%, expected to continue strong organic growth domestically.
- Acquisitions of Bliss and Jayhawk add further growth from new customers and geographies including US, Europe, and India.
- Bliss currently operates at ~30% capacity utilization, expected to ramp to 60%-70% driving revenue growth.
2 more points from Anupam Rasayan India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current order book stands at around INR 14,000 crores.
- On a 6 to 7-year average, the company anticipates adding INR 2,200 crores in incremental annual revenue from the existing pipeline.
- Of this incremental revenue, INR 1,700-1,800 crores is expected to come from agro and polymer segments.
- Additional new projects in the polymer business are expected to drive further growth.
- The pharma segment is also continuously growing organically, primarily from the Indian market.
2 more points from Anupam Rasayan India Ltd's call on order book
Create a free account to keep reading this call
Anupam Rasayan India Ltd — Quarterly revenue & net profit
Anupam Rasayan India Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 636 | 500 | +27.2% | 512 | +24.2% |
| Operating profit (EBITDA) | 137 | 144 | -4.9% | 127 | +7.9% |
| Operating margin | 22% | 29% | -7 pp | 25% | -3 pp |
| Profit before tax | 56 | 88 | -36.4% | 60 | -6.7% |
| Net profit (PAT) | 56 | 63 | -11.1% | 61 | -8.2% |
| EPS (₹) | 3.75 | 4.05 | -7.4% | 4.31 | -13% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹806 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anupam Rasayan's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Indian Phosphate (Q4 FY26)
H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In
- Paragon Fine (Q4 FY26)
Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p
- IVP (Q4 FY26)
Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector
- Vishnu Chemicals (Q4 FY26)
Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anupam Rasayan India Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anupam Rasayan India Ltd Q4 FY26 results?
Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals. Anupam Rasayan expects a 20-30% CAGR growth over the next 3-5 years in standalone business revenues, driven primarily by Pharma and Polymer segments.
What is Anupam Rasayan India Ltd share price analysis?
Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anupam Rasayan India Ltd planning capital expenditure?
Ongoing INR250 crores capex at Halol facility is for the CDMO business tied to a major multinational pharma client; it is separate from other plant capex and has a longer gestation period with expected 4x-5x asset turnover.
Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
